The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity

Biochemical Journal

Volumn 382, Issue 1, 2004, Pages 261-268

  Welsh, Michael ^a   Welsh, Charlotte ^a   Ekman, Maria ^a   Dixelius, Johan ^a   Hägerkvist, Robert ^a   Annerén, Cecilia ^a   Åkerblom, Björn ^a   Mahboobi, Siavosh ^b   Chandrasekharan, Subhashini ^c   Liu, Edison T ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

cell; Cytokine; Cytotoxicity; Fyn related kinase (FRK) RAK; Kinase inhibitor; Knockout

Indexed keywords

AUTOPHOSPHORYLATION; CYTOKINES; KINASE;

CELLS; ENZYME INHIBITION; INFILTRATION; NITROGEN COMPOUNDS; TOXICITY;

ENZYMES;

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AG 1872; AG 30; AG 370; AG 957; CYTOKINE; D 65495; D 68129; GENISTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NITRIC OXIDE; PROTEIN KINASE FYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SU 1498; SU 4984; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHOSPHORYLATION; BACULOVIRUS; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; INSECT; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PEPTIDE MAPPING; PRIORITY JOURNAL; SRC HOMOLOGY DOMAIN;

ANIMALS; CELL DEATH; CELL LINE; CYTOKINES; ENZYME INHIBITORS; INSECTS; ISLETS OF LANGERHANS; MACROPHAGE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM PROTEINS; PHOSPHOPEPTIDES; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; SRC-FAMILY KINASES; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 4344570699     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20040285     Document Type: Article

References (50)

1. Freiesleben De Blasio, B., Bak, P., Pociot, F., Karlsen, A. E. and Nerup, J. (1999) Onset of type 1 diabetes: a dynamical instability. Diabetes 48, 1677-1685
2. Rothe, H. and Kolb, H. (1998) The APC1 concept of type I diabetes. Autoimmunity 27, 179-184
3. Rabinovitch, A. (1998) An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 14, 129-151
4. Mandrup-Poulsen, T. (2001) β-Cell apoptosis: stimuli and signaling. Diabetes 50, (Suppl. 1), S58-S63
5. Petrovsky, N. and Schatz, D. A. (2003) The immunology of human type 1 diabetes. In Textbook of Diabetes, vol. 1 (Pickup, J. C. and Williams, G., eds.), pp. 18.1-18.14, Blackwell, Malden, MA
6. Cance, W. G., Craven, R. J., Bergman, M., Xu, L., Alitalo, K. and Liu, E. T. (1994) Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell Growth Differ. 5, 1347-1355
7. Lee, J., Wang, Z., Luoh, S. M., Wood, W. I. and Scadden, D. T. (1994) Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene. Gene 138, 247-251
8. Oberg-Welsh, C. and Welsh, M. (1995) Cloning of BSK, a murine FRK homologue with a specific pattern of tissue distribution. Gene 152, 239-242
9. Thuveson, M., Albrecht, D., Zurcher, G., Andres, A. C. and Ziemiecki, A. (1995) lyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine. Biochem. Biophys. Res. Commun. 209, 582-589
10. Oberg-Welsh, C., Anneren, C. and Welsh, M. (1998) Mutation of C-terminal tyrosine residues Y497/Y504 of the Src-family member Bsk/lyk decreases NIH3T3 cell proliferation. Growth Factors 16, 111-124
11. Anneren, C. and Welsh, M. (2000) Role of the Bsk/lyk non-receptor tyrosine kinase for the control of growth and hormone production in RINm5F cells. Growth Factors 17, 233-247
12. Anneren, C. and Welsh, M. (2001) Increased cytokine-induced cytotoxicity of pancreatic islet cells from transgenic mice expressing the Src-like tyrosine kinase GTK. Mol. Med. 7, 301-310
13. Anneren, C. (2002) Dual role of the tyrosine kinase GTK and the adaptor protein SHB in β-cell growth: enhanced β-cell replication after 60% pancreatectomy and increased sensitivity to streptozotocin. J. Endocrinol. 172, 145-153
14. 1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J. Med. Chem. 45, 1002-1018
15. Boyle, W. J., van der Geer, P. and Hunter, T. (1991) Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201, 110-149
16. Aebersold, R. H., Leavitt, J., Saavedra, R. A., Hood, L. E. and Kent, S. B. (1987) Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose. Proc. Natl. Acad. Sci. U.S.A. 84, 6970-6974
17. Chandrasekharan, S., Qiu, T. H., Alkharouf, N., Brantley, K., Mitchell, J. B. and Liu, E. T. (2002) Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/Rak. Mol. Cell. Biol. 22, 5235-5247
18. Saldeen, J. (2000) Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable pathway in rat insulin-producing cells. Endocrinology 141, 2003-2010
19. Kmiecik, T. E. and Shalloway, D. (1987) Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell (Cambridge, Mass.) 49, 65-73
20. Anneren, C. and Welsh, M. (2002) GTK tyrosine kinase-induced alteration of IRS-protein signalling in insulin producing cells. Mol. Med. 8, 705-713
21. Da Silva Xavier, G., Qian, Q., Cullen, P. J. and Rutter, G. A. (2004) Distinct roles for insulin and insulin-like growth factor-1 receptors in pancreatic β-cell glucose sensing revealed by RNA silencing. Biochem. J. 377, 149-158
22. 2+ homeostasis revealed by RNA silencing. Diabetes 53, 393-400
23. Kulkarni, R. N., Bruning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A. and Kahn, C. R. (1999) Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell (Cambridge, Mass.) 96, 329-339
24. Corbett, J. A. and McDaniel, M. L. (1992) Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes 41, 897-903
25. Eizirik, D. L., Flodstrom, M., Karlsen, A. E. and Welsh, N. (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic β cells. Diabetologia 39, 875-890
26. Liu, D., Pavlovic, D., Chen, M. C., Flodstrom, M., Sandler, S. and Eizirik, D. L. (2000) Cytokines induce apoptosis in β-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (INOS-/-). Diabetes 49, 1116-1122
27. Superti-Furga, G. and Gonfloni, S. (1997) A crystal milestone: the structure of regulated Src. Bioessays 19, 447-450
28. Welsh, M., Christmansson, L., Karlsson, T., Sandler, S. and Welsh, N. (1999) Transgenic mice expressing Shb adaptor protein under the control of rat insulin promoter exhibit altered viability of pancreatic islet cells. Mol. Med. 5, 169-180
29. Welsh, N. (1994) A role for tyrosine kinase activation in interteukin-1 β induced nitric oxide production in the insulin producing cell line RINm-5F. Biosci. Rep. 14, 43-50
30. Corbett, J. A., Kwon, G., Marino, M. H., Rodi, C. P., Sullivan, P. M., Turk, J. and McDaniel, M. L. (1996) Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. Am. J. Physiol. 270, C1581-C1587
31. Schwartz, B., Lamprecht, S. A., Polak-Charcon, S., Niv, Y. and Kim, Y. S. (1995) Induction of the differentiated phenotype in human colon cancer cell is associated with the attenuation of subcellular tyrosine phosphorylation. Oncol. Res. 7, 277-287
32. Wessely, O., Mellitzer, G., von Lindern, M., Levitzki, A., Gazit, A., Ischenko, I., Hayman, M. J. and Beug, H. (1997) Distinct roles of the receptor tyrosine kinases c-ErbB and c-Kit in regulating the balance between erythroid cell proliferation and differentiation. Cell Growth Differ. 8, 481-493
33. Bryckaert, M. C., Eldor, A., Fontenay, M., Gazit, A., Osherov, N., Gilon, C., Levitzki, A. and Tobelem, G. (1992) Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. Exp. Cell Res. 199, 255-261
34. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A. and Gazit, A. et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (London) 379, 645-648
35. Nielsen, M., Kaltoft, K., Nordahl, M., Ropke, C., Geisler, C., Mustelin, T., Dobson, P., Svejgaard, A. and Odum, N. (1997) Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 94, 6764-6769
36. Ohmichi, M., Pang, L., Ribon, V., Gazit, A., Levitzki, A. and Saltiel, A. R. (1993) The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry 32, 4650-4658
37. Anafi, M., Gazit, A., Gilon, C., Ben-Neriah, Y. and Levitzki, A. (1992) Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J. Biol. Chem. 267, 4518-4523
38. Kaur, G. and Sausville, E. A. (1996) Altered physical state of p210bcr-abl in tyrphostin AG957-treated K562 cells. Anticancer Drugs 7, 815-824
39. Parrizas, M., Gazit, A., Levitzki, A., Wertheimer, E. and LeRoith, D. (1997) Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138, 1427-1433
40. Kovalenko, M., Gazit, A., Bohmer, A., Rorsman, C., Ronnstrand, L., Heldin, C. H., Waltenberger, J., Bohmer, F. D. and Levitzki, A. (1994) Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54, 6106-6114
41. Banai, S., Wolf, Y., Golomb, G., Pearle, A., Waltenberger, J., Fishbein, I., Schneider, A., Gazit, A., Perez, L. and Huber, R. et al. (1998) PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97, 1960-1969
42. Kovalenko, M., Ronnstrand, L., Heldin, C. H., Loubtchenkov, M., Gazit, A., Levitzki, A. and Bohmer, F. D. (1997) Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 36, 6260-6269
43. Eguchi, S., Numaguchi, K., Iwasaki, H., Matsumoto, T., Yamakawa, T., Utsunomiya, H., Motley, E. D., Kawakatsu, H., Owada, K. M. and Hirata, Y. et al. (1998) Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J. Biol. Chem. 273, 8890-8896
44. Liu, W., Akhand, A. A., Kato, M., Yokoyama, I., Miyata, T., Kurokawa, K., Uchida, K. and Nakashima, I. (1999) 4-Hydroxynonenal triggers an epidermal growth factor receptor-linked signal pathway for growth inhibition. J. Cell Sci. 112, 2409-2417
45. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A. and Connelly, P. A. (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271, 695-701
46. Constantinou, A. and Huberman, E. (1995) Genistein as an inducer of tumor cell differentiation: possible mechanisms of action. Proc. Soc. Exp. Biol. Med. 208, 109-115
47. Salazar, E. P. and Rozengurt, E. (1999) Bombesin and platelet-derived growth factor induce association of endogenous focal adhesion kinase with Src in intact Swiss 3T3 cells. J. Biol. Chem. 274, 28371-28378
48. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A. and Gazit, A. et al. (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res. 56, 3540-3545
49. Arbiser, J. L., Larsson, H., Claesson-Welsh, L., Bai, X., LaMontagne, K., Weiss, S. W., Soker, S., Flynn, E. and Brown, L. F. (2000) Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am. J. Pathol. 156, 1469-1476
50. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R. and Schlessinger, J. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955-960